Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Description Myasthenia gravis (MG) is a rare autoimmune disorder which causes the muscles to become weak because the immune system attacks the connection between the nerves and the muscles.

Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). An immunoglobin is a blood protein. Hizentra is being studied for the treatment of patients with MG. Hizentra is administered by an injection into the skin through a portable infusion pump, which may be easier for patients to administer than the current treatments.

Participants will be asked to complete 9 clinic visits and 3 telephone calls. It could take up to 30 weeks to complete all study visits.

Study visits will be at Erie County Medical Center
Objective The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).
Principal Investigator SILVESTRI, NICHOLAS
Age Group Adult
Drugs Involved
Status Open
Key Eligibility ages 18 and older
Myasthenia Gravis
Disease Group Autoimmune Disorders; Brain/Neurological Disorders
Treatment Subcutaneous Immunoglobulin (SCIg)